Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
130.72
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
March 26, 2024
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in...
Via
Benzinga
Smart Money Is Betting Big In MRK Options
March 25, 2024
Via
Benzinga
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
March 24, 2024
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Looking At Merck & Co's Recent Unusual Options Activity
March 20, 2024
Via
Benzinga
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
March 13, 2024
Via
Benzinga
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
March 21, 2024
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression.
Via
Benzinga
Bull Market and Beyond: 2 Stocks to Buy and Hold Forever
March 21, 2024
These stocks have been providing excellent returns for a long time.
Via
The Motley Fool
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
March 21, 2024
From
Merck & Co., Inc.
Via
Business Wire
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
March 20, 2024
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
March 20, 2024
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel
Via
MarketBeat
Exposures
Product Safety
Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine
March 19, 2024
Merck's Phase 3 data on V116, a 21-valent pneumococcal conjugate vaccine for adults, show promising immunogenicity across diverse populations, including those at risk.
Via
Benzinga
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
March 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
March 18, 2024
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity...
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, March 16
March 16, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of March 11-15, 2024.
Via
Talk Markets
Newly Diagnosed Cervical Cancer Patients - Merck's Blockbuster Drug Keytruda Plus Chemoradiotherapy Improves Overall Survival
March 15, 2024
Merck's Keytruda in combination with chemoradiotherapy achieves significant improvement in overall survival for newly diagnosed high-risk locally advanced cervical cancer patients. Keytruda is the...
Via
Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
March 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
March 14, 2024
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target...
Via
Benzinga
7 Dow Darlings for Investors to Buy for March Market Madness
March 13, 2024
These 7 Dow stocks are better positioned than the other 23 within the index making them strong buy considerations.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
SCHD ETF Spotlight: The Top 6 Stocks Inside This Dividend Monster
March 13, 2024
With over 100 dividend growth stocks in its portfolio, the SCHD ETF has proved to be a formidable income-generating vehicle for investors.
Via
InvestorPlace
Topics
ETFs
Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
March 13, 2024
From
Merck & Co., Inc.
Via
Business Wire
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
March 11, 2024
Moderna and Merck are now testing their cancer vaccine in patients with another form of skin cancer.
Via
Investor's Business Daily
What's Going On With Moderna Stock On Monday?
March 11, 2024
Merck's trial with Moderna's V940 for advanced cutaneous squamous cell carcinoma. The neoadjuvant and adjuvant therapy with pembrolizumab, aiming for superior event-free survival. Phase 3 expansion...
Via
Benzinga
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
March 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
March 09, 2024
These businesses can pack a punch in your portfolio over the long run.
Via
The Motley Fool
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
March 06, 2024
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.
Via
Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.